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CNS derived Extracellular Vesicles as 
Biomarkers in Multiple Sclerosis 
(MS)
By Anshel Kenkare, with advisor 
Dr. Abdolmohamad Rostami  (*)
Introduction
• MS is a clinically heterogenous disease making it difficult to diagnose 
arising from a demyelinating pathology
• Initiating treatment of MS early has been shown to improve patient 
outcomes and slow disease progression
• This study aims to find biomarkers to categorize biological changes in MS 
(through extracellular vesicles containing oligodendrocyte proteins) à
Earlier and more accurate clinical decision making!
Introduction
• Extracellular vesicles can help categorize 
autoimmune disease






– How do the extracellular vesicles contents of 
cerebrospinal fluid (CSF) and blood compare between 
unmedicated patients diagnosed with MS and non-
inflammatory headache controls?
• Hypothesis
– There will be a greater number of extracellular 
vesicles visible in the CSF and blood of unmedicated 
MS patients compared to healthy controls. 
Furthermore, vesicles in the unmedicated patients 
with MS will show signs of immune dysregulation.
Approach
MS Patients Headache Patients
Receiving a lumbar puncture for 
clinical care
Consent to have a 
non-clinically 
significant portion of 






















- 7 confirmed MS CSF samples and 10 Headache CSF 
samples were received
- 3 non-confirmed MS patients à 1 radiologically isolated 
syndrome and 2 patients with a high suspicion
- All of these patients provided blood samples
- 5 MS and Headache patients also provided blood
- Vesicles were visualized for each sample to confirm 
presence and count is being conducted
- Metabolomic analysis is currently being conducted on 
the samples and will be available March 15th
Initial Metabolomic Analysis
Conclusions
• Currently we are waiting on the majority of the data
– Initial data 
• Suggests that EVs can provide inflammatory 
markers better than isolated CSF
• Blood is most likely not as useful for categorizing 
MS at its diagnostic phase
• Counted EV samples show increased EVs in control 
samples à This is being further analyzed
– Complete Data
• Will be available in March 
Backup Plan
Future Directions
• Repeating the experiment on a larger sample size of frozen CSF to confirm the 
results
• We expect to find novel biomarkers that can show signs of damage in MS
– In future research, we would hope to sub stratify and look for changes in biomarkers 
associated with progression in MS. This could be helpful as in MS progression, biological 
pathology often arises before clinical symptom onset
• We hope the new biomarkers determined will lead to more research into using 
extracellular vesicles as diagnostic tools and hope the biomarkers will provide 
further insight into the underlying pathology of MS
• If data holds up for vesicle count being increased analyzing vesicular membrane 
integrity may be a future avenue for investigation
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